Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Sep 08, 2023 1:23pm
63 Views
Post# 35626486

RE:RE:RE:RE:RE:RE:RE:Well?

RE:RE:RE:RE:RE:RE:RE:Well?Hi PWIB123

Having neuroendocrine cancer myself, not rectal but ileum, can you tell me which chemo your dad got in 2015, and what he is starting on now? Hope for the best.

PWIB123 wrote: Appreciate the prayers SPCEO1.  Dad started chemo again finally Tuesday this week, so now we wait and see how he responds.  Prayers are coveted.  This is dad's second time having Stage IV high grade neuroendocrine rectal cancer.  MD Anderson wants him to receive 4 treatment cycles before they reassess to decide if the current treatment regiment should be modified.  MD Anderson couldn't believe the cancer responded to the treatment dad received back in 2015, because of the tumor type.  I know it was a miracle and not the chemo, but they are trying the same chemo treatement again, even though they admitted that they wouldn't have initially prescribed it due to be neuroendocrine.  

I've never understood what seems to be an inordinate amount of time for the blackout excuse to be used as to why insiders may not be buying.  It does make sense now that financials are being prepared, but not necessarily over the last 60 days.  I suppose they could have some major announcement coming that would forbid them from trading, but I would be surprised.

How can investors find out what the company policy is around blackout periods?

https://www.naspp.com/blog/4-Trends-in-Trading-Blackout-Periods


<< Previous
Bullboard Posts
Next >>